Table 2. Replication analysis: risk estimates for serous invasive ovarian cancer in non-Hispanic whites for SNPs selected for replication by indicated OCAC sites.
| Gene | SNP | MAFa | Controls | Cases | ORHet b | (95% CI) | P | ORHom b | (95% CI) | P | ORper-allele b | (95% CI) | P | OCAC Studiesc |
| PODXL | rs1013368 | 0.38 | 6,308 | 2,173 | 1.00 | (0.89–1.10) | 0.88 | 1.02 | (0.88–1.18) | 0.81 | 1.01 | (0.94–1.08) | 0.88 | AUS, DOV, GER, HAW, HOP, MAL, POL, SEA, STA, UCI, USC, UKO |
| ITGA6 | rs13027811 | 0.10 | 8,005 | 2,660 | 1.03 | (0.92–1.16) | 0.57 | 1.04 | (0.67–1.61) | 0.87 | 1.03 | (0.93–1.14) | 0.57 | AUS, DOV, HAW, HOP, MAL, MAY, NCO, NEC, NHS, POL, SEA, UCI, UKO, USC |
| MMP3 | rs522616 | 0.20 | 8,773 | 2,985 | 1.03 | (0.94–1.12) | 0.58 | 1.03 | (0.84–1.27) | 0.74 | 1.02 | (0.96–1.10) | 0.55 | AUS, DOV, GER, HAW, HOP, MAL, MAY, NCO, NEC, NHS, POL, SEA, STA, UCI, UKO, USC |
| PODXL | rs11768640 | 0.24 | 2,952 | 1,076 | 0.92 | (0.79–1.06) | 0.25 | 0.86 | (0.62–1.18) | 0.35 | 0.92 | (0.82–1.04) | 0.17 | AUS, MAL, SEA, UKO, USC |
| PODXL | rs4731799 | 0.47 | 2,954 | 1,077 | 0.94 | (0.80–1.11) | 0.48 | 1.03 | (0.85–1.25) | 0.75 | 1.01 | (0.92–1.12) | 0.82 | AUS, MAL, SEA, UKO, USC |
| ITGA6 | rs1574028 | 0.09 | 2,958 | 1,080 | 1.00 | (0.83–1.21) | 0.98 | 1.10 | (0.54–2.23) | 0.79 | 1.01 | (0.85–1.20) | 0.89 | AUS, MAL, SEA, UKO, USC |
| MMP7 | rs17098236 | 0.08 | 2,945 | 1,074 | 1.14 | (0.95–1.37) | 0.17 | 2.34 | (1.04–5.26) | 0.04 | 1.19 | (1.01–1.42) | 0.04 | AUS, MAL, SEA, UKO, USC |
| MMP26 | rs11035042 | 0.11 | 2,957 | 1,080 | 1.04 | (0.88–1.24) | 0.63 | 0.63 | (0.30–1.31) | 0.21 | 0.99 | (0.84–1.16) | 0.89 | AUS, MAL, SEA, UKO, USC |
| FN1 | rs1250229 | 0.26 | 2,954 | 1,075 | 0.92 | (0.79–1.07) | 0.26 | 1.01 | (0.76–1.34) | 0.96 | 0.96 | (0.86–1.08) | 0.50 | AUS, MAL, SEA, UKO, USC |
| PLOD2 | rs1512900 | 0.47 | 2,942 | 1,070 | 0.89 | (0.76–1.05) | 0.16 | 0.85 | (0.69–1.04) | 0.11 | 0.92 | (0.83–1.01) | 0.09 | AUS, MAL, SEA, UKO, USC |
| PANX1 | rs1540177 | 0.40 | 2,956 | 1,079 | 0.94 | (0.80–1.10) | 0.42 | 1.18 | (0.96–1.45) | 0.12 | 1.06 | (0.96–1.17) | 0.28 | AUS, MAL, SEA, UKO, USC |
| PTTG1 | rs17057781 | 0.14 | 2,954 | 1,079 | 1.04 | (0.88–1.22) | 0.67 | 1.32 | (0.82–2.15) | 0.25 | 1.07 | (0.93–1.23) | 0.36 | AUS, MAL, SEA, UKO, USC |
| CSF1 | rs1999713 | 0.35 | 2,957 | 1,076 | 0.95 | (0.82–1.11) | 0.54 | 1.09 | (0.87–1.36) | 0.45 | 1.02 | (0.92–1.13) | 0.75 | AUS, MAL, SEA, UKO, USC |
| PTEN | rs34370136 | 0.06 | 2,957 | 1,079 | 0.86 | (0.68–1.09) | 0.22 | 0.53 | (0.12–2.44) | 0.42 | 0.85 | (0.68–1.06) | 0.15 | AUS, MAL, SEA, UKO, USC |
| LCN2 | rs3814526 | 0.04 | 2,957 | 1,079 | 1.20 | (0.94–1.52) | 0.14 | 0.38 | (0.05–3.12) | 0.37 | 1.14 | (0.91–1.44) | 0.25 | AUS, MAL, SEA, UKO, USC |
| TIMP3 | rs5754289 | 0.17 | 2,942 | 1,076 | 1.02 | (0.87–1.19) | 0.81 | 0.93 | (0.62–1.41) | 0.74 | 1.00 | (0.88–1.14) | 0.99 | AUS, MAL, SEA, UKO, USC |
| DDR2 | rs6693632 | 0.05 | 2,954 | 1,080 | 0.86 | (0.67–1.12) | 0.27 | 0.36 | (0.04–2.93) | 0.34 | 0.84 | (0.66–1.08) | 0.18 | AUS, MAL, SEA, UKO, USC |
| DDR2 | rs6702820 | 0.24 | 2,954 | 1,080 | 0.88 | (0.76–1.02) | 0.09 | 0.89 | (0.64–1.22) | 0.46 | 0.91 | (0.80–1.02) | 0.10 | AUS, MAL, SEA, UKO, USC |
| DDR2 | rs10917589 | 0.07 | 2,955 | 1,079 | 1.00 | (0.81–1.24) | 0.97 | 1.62 | (0.74–3.56) | 0.23 | 1.05 | (0.87–1.27) | 0.59 | AUS, MAL, SEA, UKO, USC |
| TERT | rs7726159 | 0.33 | 2,952 | 1,079 | 1.18 | (1.02–1.37) | 0.03 | 1.21 | (0.95–1.53) | 0.12 | 1.12 | (1.01–1.25) | 0.03 | AUS, MAL, SEA, UKO, USC |
aMAF in controls.
bORs, 95% CI and p-values are adjusted for age (at interview in controls, at diagnosis in cases) and study site.
cOCAC studies not listed for PODXL rs1013368, ITGA6 rs13027811 and MMP3 rs522616 were excluded from analysis because of QC failures.